Better Brain for All

Better Brain is a French biotechnology company focused on developing neuroprotective therapies for acute and chronic neurological conditions. The company's lead candidate, BB-001, is a first-in-class peptide designed to prevent neuronal death following ischemic stroke and traumatic brain injury by targeting specific excitotoxic pathways. Better Brain aims to address the significant unmet need in neuroprotection by preserving brain function and improving clinical outcomes for patients suffering from brain injuries and neurodegenerative diseases. The company's approach involves disrupting the interaction between the NMDA receptor and the scaffolding protein PSD-95, thereby blocking cell death signaling without affecting normal synaptic activity.